Novavax, Inc. (NASDAQ:NVAX) has received an average rating of “Hold” from the eleven ratings firms that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, eight have issued a hold recommendation and two have given a buy recommendation to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $3.35.

Several research analysts have recently commented on the company. Cantor Fitzgerald reissued a “hold” rating and issued a $2.00 target price on shares of Novavax in a report on Friday, July 21st. BidaskClub downgraded Novavax from a “hold” rating to a “sell” rating in a report on Wednesday, July 19th. Seaport Global Securities reissued a “neutral” rating on shares of Novavax in a report on Friday, October 6th. Zacks Investment Research downgraded Novavax from a “buy” rating to a “hold” rating in a report on Wednesday, July 26th. Finally, Piper Jaffray Companies reissued a “hold” rating and issued a $1.50 target price on shares of Novavax in a report on Wednesday, July 26th.

COPYRIGHT VIOLATION NOTICE: “Novavax, Inc. (NVAX) Receives Consensus Rating of “Hold” from Brokerages” was reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The correct version of this story can be read at https://www.americanbankingnews.com/2017/10/11/novavax-inc-nvax-receives-consensus-rating-of-hold-from-brokerages.html.

Shares of Novavax (NASDAQ:NVAX) traded down 0.85% during mid-day trading on Wednesday, hitting $1.16. The stock had a trading volume of 4,619,453 shares. The stock’s market cap is $336.28 million. The firm has a 50 day moving average of $1.13 and a 200 day moving average of $1.06. Novavax has a one year low of $0.73 and a one year high of $1.93.

Novavax (NASDAQ:NVAX) last released its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.16). The company had revenue of $6.70 million for the quarter, compared to the consensus estimate of $6.15 million. Novavax had a negative return on equity of 787.38% and a negative net margin of 1,006.00%. The company’s quarterly revenue was up 168.0% on a year-over-year basis. During the same period in the previous year, the business earned ($0.29) earnings per share. On average, analysts forecast that Novavax will post ($0.62) earnings per share for the current year.

In related news, Director James F. Young sold 175,000 shares of the business’s stock in a transaction that occurred on Thursday, August 31st. The shares were sold at an average price of $1.06, for a total value of $185,500.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 4.00% of the company’s stock.

Several institutional investors have recently modified their holdings of NVAX. Teachers Advisors LLC raised its position in shares of Novavax by 4.2% during the 4th quarter. Teachers Advisors LLC now owns 455,686 shares of the biopharmaceutical company’s stock valued at $574,000 after acquiring an additional 18,519 shares during the last quarter. Wells Fargo & Company MN raised its position in shares of Novavax by 2.7% during the 1st quarter. Wells Fargo & Company MN now owns 343,714 shares of the biopharmaceutical company’s stock valued at $440,000 after acquiring an additional 8,966 shares during the last quarter. Bank of New York Mellon Corp raised its position in shares of Novavax by 0.9% during the 1st quarter. Bank of New York Mellon Corp now owns 1,215,100 shares of the biopharmaceutical company’s stock valued at $1,555,000 after acquiring an additional 10,347 shares during the last quarter. JPMorgan Chase & Co. raised its position in shares of Novavax by 41.9% during the 1st quarter. JPMorgan Chase & Co. now owns 3,708,105 shares of the biopharmaceutical company’s stock valued at $4,746,000 after acquiring an additional 1,095,388 shares during the last quarter. Finally, American International Group Inc. raised its position in shares of Novavax by 7.1% during the 1st quarter. American International Group Inc. now owns 166,252 shares of the biopharmaceutical company’s stock valued at $213,000 after acquiring an additional 10,965 shares during the last quarter. Institutional investors own 45.17% of the company’s stock.

Novavax Company Profile

Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases.

Analyst Recommendations for Novavax (NASDAQ:NVAX)

Receive News & Ratings for Novavax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax Inc. and related companies with MarketBeat.com's FREE daily email newsletter.